bisoprolol has been researched along with Cardiac Remodeling, Ventricular in 17 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF)." | 9.19 | Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud ( Hori, M; Izumi, T; Matsuzaki, M; Nagai, R, 2014) |
| "In CIBIS III, initiating chronic heart failure (CHF) treatment with bisoprolol (target dose 10 mg q." | 9.14 | The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. ( Goulder, M; Meyer, WR; van de Ven, LL; van Veldhuisen, DJ; Willenheimer, R; Zilahi, Z, 2010) |
| " The purpose of this study was to compare the effects of bisoprolol therapy with those of imidapril therapy on left ventricular remodeling after acute myocardial infarction (AMI)." | 9.09 | Long-term effects of bisoprolol compared with imidapril on left ventricular remodeling after reperfusion in acute myocardial infarction: an angiographic study in patients with maintained vessel patency. ( Kojima, S; Kuramochi, M; Matsumoto, Y; Sugi, T; Yano, M; Yoshitomi, Y, 2000) |
| "Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF)." | 5.19 | Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud ( Hori, M; Izumi, T; Matsuzaki, M; Nagai, R, 2014) |
| "In CIBIS III, initiating chronic heart failure (CHF) treatment with bisoprolol (target dose 10 mg q." | 5.14 | The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. ( Goulder, M; Meyer, WR; van de Ven, LL; van Veldhuisen, DJ; Willenheimer, R; Zilahi, Z, 2010) |
| " The purpose of this study was to compare the effects of bisoprolol therapy with those of imidapril therapy on left ventricular remodeling after acute myocardial infarction (AMI)." | 5.09 | Long-term effects of bisoprolol compared with imidapril on left ventricular remodeling after reperfusion in acute myocardial infarction: an angiographic study in patients with maintained vessel patency. ( Kojima, S; Kuramochi, M; Matsumoto, Y; Sugi, T; Yano, M; Yoshitomi, Y, 2000) |
| "The historical choice of angiotensin-converting enzyme (ACE) inhibition as first-line therapy in heart failure is challenged by early activation of the sympathetic system and multiple ways beta blockade (in particular, unselective agents such as carvedilol) may affect cardiac remodeling, its underlying mechanisms, and, hence, progression of heart failure, compared with ACE inhibition." | 4.84 | Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first? ( Remme, WJ, 2007) |
| "Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle." | 3.79 | Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure. ( Agresta, A; Cannavo, A; de Lucia, C; Femminella, GD; Ferrara, N; Koch, WJ; Komici, K; Leosco, D; Liccardo, D; Pagano, G; Parisi, V; Perrone Filardi, P; Rapacciuolo, A; Rengo, G; Scala, O; Trimarco, B; Zincarelli, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SW | 1 |
| Han, S | 1 |
| Shim, WJ | 1 |
| Choi, DJ | 2 |
| Kim, YJ | 1 |
| Yoo, BS | 1 |
| Hwang, KK | 1 |
| Jeon, HK | 2 |
| Shin, MS | 1 |
| Ryu, KH | 1 |
| Hori, M | 1 |
| Nagai, R | 1 |
| Izumi, T | 1 |
| Matsuzaki, M | 1 |
| Rengo, G | 1 |
| Cannavo, A | 1 |
| Liccardo, D | 1 |
| Zincarelli, C | 1 |
| de Lucia, C | 1 |
| Pagano, G | 1 |
| Komici, K | 1 |
| Parisi, V | 1 |
| Scala, O | 1 |
| Agresta, A | 1 |
| Rapacciuolo, A | 1 |
| Perrone Filardi, P | 1 |
| Ferrara, N | 1 |
| Koch, WJ | 1 |
| Trimarco, B | 1 |
| Femminella, GD | 1 |
| Leosco, D | 1 |
| Tanaka, H | 1 |
| Matsumoto, K | 1 |
| Sawa, T | 1 |
| Miyoshi, T | 1 |
| Motoji, Y | 1 |
| Imanishi, J | 1 |
| Mochizuki, Y | 1 |
| Tatsumi, K | 1 |
| Hirata, K | 1 |
| Lee, HY | 1 |
| Chung, WJ | 1 |
| Seo, HS | 1 |
| Jeon, ES | 1 |
| Kim, JJ | 1 |
| Shin, JH | 1 |
| Kang, SM | 1 |
| Lim, SC | 1 |
| Baek, SH | 1 |
| Das, M | 1 |
| van de Ven, LL | 1 |
| van Veldhuisen, DJ | 1 |
| Goulder, M | 1 |
| Zilahi, Z | 1 |
| Meyer, WR | 1 |
| Willenheimer, R | 1 |
| Duncker, DJ | 1 |
| Boontje, NM | 1 |
| Merkus, D | 1 |
| Versteilen, A | 1 |
| Krysiak, J | 1 |
| Mearini, G | 1 |
| El-Armouche, A | 1 |
| de Beer, VJ | 1 |
| Lamers, JM | 1 |
| Carrier, L | 1 |
| Walker, LA | 1 |
| Linke, WA | 1 |
| Stienen, GJ | 1 |
| van der Velden, J | 1 |
| Remme, WJ | 2 |
| Chen, WQ | 1 |
| Cai, H | 1 |
| Zhang, C | 1 |
| Ji, XP | 1 |
| Zhang, Y | 1 |
| O-Uchi, J | 1 |
| Lopes, CM | 1 |
| Pituskin, E | 1 |
| Haykowsky, M | 1 |
| Mackey, JR | 1 |
| Thompson, RB | 1 |
| Ezekowitz, J | 1 |
| Koshman, S | 1 |
| Oudit, G | 1 |
| Chow, K | 1 |
| Pagano, JJ | 1 |
| Paterson, I | 1 |
| Mougenot, N | 1 |
| Médiani, O | 1 |
| Lechat, P | 1 |
| Tarasov, NI | 1 |
| Kokov, AN | 1 |
| Barbarash, LS | 1 |
| Yoshitomi, Y | 1 |
| Kojima, S | 1 |
| Yano, M | 1 |
| Sugi, T | 1 |
| Matsumoto, Y | 1 |
| Kuramochi, M | 1 |
| Onodera, T | 1 |
| Okazaki, F | 1 |
| Miyazaki, H | 1 |
| Minami, S | 1 |
| Ito, T | 1 |
| Seki, S | 1 |
| Taniguchi, M | 1 |
| Taniguchi, I | 1 |
| Mochizuki, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers Stratified for History of BCG-Vaccination[NCT00749034] | Phase 1 | 80 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A Prospective Study to See if Cardiac Effects of Herceptin Can be Prevented With Standard Heart Medications[NCT01016886] | Phase 1/Phase 2 | 99 participants (Actual) | Interventional | 2010-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for bisoprolol and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2007 |
5 trials available for bisoprolol and Cardiac Remodeling, Ventricular
11 other studies available for bisoprolol and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Impact of Heart Rate Reduction with Maximal Tolerable Dose of Bisoprolol on Left Ventricular Reverse Remodeling.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Age Factors; Aged; Bisoprolol; Female; Heart Failure; | 2018 |
Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Bisoprolol; Coronary Circulation; Disease Models, A | 2013 |
Evaluation of global circumferential strain as prognostic marker after administration of β-blockers for dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Area Under Curve; Bisoprolol; Carbazoles; Cardiomyopathy, | 2014 |
Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Bisoprolol; Female; Gene Frequency; Genotype; H | 2016 |
Small benefits in trastuzumab-related cardiotoxicity.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Age | 2017 |
Prevention of myofilament dysfunction by beta-blocker therapy in postinfarct remodeling.
Topics: Actin Cytoskeleton; Adrenergic beta-Antagonists; Animals; Bisoprolol; Calcium Signaling; Cardiac Myo | 2009 |
Which beta-blocker is most effective in heart failure?
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria | 2010 |
Is overall blockade superior to selective blockade of adrenergic receptor subtypes in suppressing left ventricular remodeling in spontaneously hypertensive rats?
Topics: Adrenergic Antagonists; Animals; Apoptosis; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Dise | 2010 |
Combined blockade of β- and α₁-adrenoceptors in left ventricular remodeling induced by hypertension: beneficial or not?
Topics: Adrenergic Antagonists; Animals; Bisoprolol; Carbazoles; Carvedilol; Disease Models, Animal; Humans; | 2010 |
Bisoprolol and hydrochlorothiazide effects on cardiovascular remodeling in spontaneously hypertensive rats.
Topics: Animals; Bisoprolol; Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug T | 2005 |
Perindopril reverses myocyte remodeling in the hypertensive heart.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bisoprolol; Cell Cou | 2002 |